PET/CT in cancer research: From preclinical to clinical applications (617 views)
Contrast Media Mol Imaging (ISSN: 1555-4309, 1555-4309linking), 2010 Jul; 5(4): 190-200.
Export to BibTeX Export to EndNote
Paper type: Journal Article, Review,
Impact factor: 4.02, 5-year impact factor: 4.149
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-77956139255&partnerID=40&md5=fc9f8842f054a65507ace506d3efbe67
Keywords: Cancer, Pet Ct, Translational Research, Fluorothymidine F 18, 4 (3 Bromoanilino) 6, 7 Dimethoxyquinazoline, 6 (4 Hydroxyphenyl) 4 (alpha Methylbenzylamino) 7h Pyrrolo[2, 3 D]pyrimidine, Bevacizumab, Cetuximab, Cisplatin, Cyclophosphamide, Doxorubicin, Epidermal Growth Factor Receptor Kinase Inhibitor, Erlotinib, Fluorodeoxyglucose F 18, Fluorouracil, Gefitinib, Histone Deacetylase Inhibitor, Irinotecan, Prednisone, Rituximab, Tracer, Trastuzumab, Tumor Marker, Vincristine, Angiogenesis, Apoptosis, Breast Cancer, Cancer Cell, Cancer Diagnosis, Cancer Invasion, Cancer Research, Cell Proliferation, Colon Carcinoma, Computer Assisted Tomography, Drug Mechanism, Fibrosarcoma, Follicular Lymphoma, Gene Targeting, Glioblastoma, Human, Lung Non Small Cell Cancer, Metastasis, Nonhuman, Positron Emission Tomography, Priority Journal, Protein Expression, Review, Squamous Cell Carcinoma, Treatment Response, Animals, Neoplasms, Positron-Emission Tomography, X-Ray Computed, Neoplasms Diagnosis Radiography Radionuclide Imaging, Positron-Emission Tomography Methods, X-Ray Computed Methods, 6 (4 Hydroxyphenyl) 4 (alpha Methylbenzylamino) 7h Pyrrolo [2, 3 D] Pyrimidine, Neoplasms Diagnosis Diagnostic Imaging,
Affiliations:
*** IBB - CNR ***
Department of Biomorphological and Functional Sciences, University of Naples 'Federico II', Edificio 10, Via S. Pansini, 5, Naples 80131, Italy
Institute of Biostructures and Bioimages, National Research Council, Naples, Italy
References:
Hanahan, D., Weinberg, R.A., The hallmarks of cancer (2000) Cell, 100, pp. 57-7
Kang, J.H., Chung, J.K., Molecular-genetic imaging based on reporter gene expression (2008) J Nucl Med, 49 (SUPPL. 2), pp. 164S-179S
Bading, J.R., Shields, A.F., Imaging of cell proliferation: Status and prospects (2008) J Nucl Med, 49 (SUPPL. 2), pp. 64S-80S
Salskov, A., Tammisetti, V.S., Grierson, J., Vesselle, H., FLT: Measuring tumor cell proliferation in vivo with positron emission tomography and 3′-deoxy-3′-(18F)fluorothymidine (2007) Semin Nucl Med, 37, pp. 429-439
Buck, A.K., Schirrmeister, H., Hetzel, M., Von Der Heide, M., Halter, G., Glatting, G., Mattfeldt, T., Neumaier, B., 3-deoxy-3-((18)F)fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules (2002) Cancer Res, 62, pp. 3331-3334
Vesselle, H., Grierson, J., Muzi, M., Pugsley, J.M., Schmidt, R.A., Rabinowitz, P., Peterson, L.M., Wood, D.E., In vivo validation of 3′deoxy-3′-((18)F)fluorothymidine (((18)F)FLT) as a proliferation imaging tracer in humans: Correlation of ((18)F)FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors (2002) Clin Cancer Res, 8, pp. 3315-3323
Dittmann, H., Dohmen, B.M., Paulsen, F., Eichhorn, K., Eschmann, S.M., Horger, M., Wehrmann, M., Bares, R., (18F)FLT PET for diagnosis and staging of thoracic tumours (2003) Eur J Nucl Med Mol Imag, 30, pp. 1407-1412
Buck, A.K., Halter, G., Schirrmeister, H., Kotzerke, J., Wurziger, I., Glatting, G., Mattfeldt, T., Hetzel, M., Imaging proliferation in lung tumors with PET:18F-FLT versus 18F-FDG (2003) J Nucl Med, 44, pp. 1426-1431
Muzi, M., Vesselle, H., Grierson, J.R., Mankoff, D.A., Schmidt, R.A., Peterson, L., Wells, J.M., Krohn, K.A., Kinetic analysis of 3′-deoxy- 3′-fluorothymidine PET studies: Validation studies in patients with lung cancer (2005) J Nucl Med, 46, pp. 274-282
Buck, A.K., Hetzel, M., Schirrmeister, H., Halter, G., Moller, P., Kratochwil, C., Wahl, A., Reske, S.N., Clinical relevance of imaging proliferative activity in lung nodules (2005) Eur J Nucl Med Mol Imag, 32, pp. 525-533
Yap, C.S., Czernin, J., Fishbein, M.C., Cameron, R.B., Schiepers, C., Phelps, M.E., Weber, W.A., Evaluation of thoracic tumors with18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography (2006) Chest, 129, pp. 393-401
Van Westreenen, H.L., Cobben, D.C., Jager, P.L., Van Dullemen, H.M., Wesseling, J., Elsinga, P.H., Plukker, J.T., Comparison of18F-FLT PET and18F-FDG PET in esophageal cancer (2005) J Nucl Med, 46, pp. 400-404
Francis, D.L., Visvikis, D., Costa, D.C., Arulampalam, T.H., Townsend, C., Luthra, S.K., Taylor, I., Ell, P.J., Potential impact of (18F)3′-deoxy- 3′- fluorothymidine versus (18F)fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer (2003) Eur J Nucl Med Mol Imag, 30, pp. 988-994
Visvikis, D., Francis, D., Mulligan, R., Costa, D.C., Croasdale, I., Luthra, S.K., Taylor, I., Ell, P.J., Comparison of methodologies for the in vivo assessment of18FLT utilisation in colorectal cancer (2004) Eur J Nucl Med Mol Imag, 31, pp. 169-178
Wagner, M., Seitz, U., Buck, A., Neumaier, B., Schultheiss, S., Bangerter, M., Bommer, M., Reske, S.N., 3′-(18F)fluoro-3′-deoxythymidine (( 18F)-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease (2003) Cancer Res, 63, pp. 2681-2687
Jacobs, A.H., Thomas, A., Kracht, L.W., Li, H., Dittmar, C., Garlip, G., Galldiks, N., Heiss, W.D., 18F-fluoro-L-thymidine and11C-methylmethionine as markers of increased transport and proliferation in brain tumors (2005) J Nucl Med, 46, pp. 1948-1958
Choi, S.J., Kim, J.S., Kim, J.H., Oh, S.J., Lee, J.G., Kim, C.J., Ra, Y.S., Moon, D.H., (18F)3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors (2005) Eur J Nucl Med Mol Imag, 32, pp. 653-659
Chen, W., Cloughesy, T., Kamdar, N., Satyamurthy, N., Bergsneider, M., Liau, L., Mischel, P., Silverman, D.H., Imaging proliferation in brain tumors with18F-FLT PET: Comparison with18F-FDG (2005) J Nucl Med, 46, pp. 945-952
Kenny, L.M., Vigushin, D.M., Al-Nahhas, A., Osman, S., Luthra, S.K., Shousha, S., Coombes, R.C., Aboagye, E.O., Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by (18F)fluorothymidine-positron emission tomography imaging: Evaluation of analytical methods (2005) Cancer Res, 65, pp. 10104-11012
Leyton, J., Latigo, J.R., Perumal, M., Dhaliwal, H., He, Q., Aboagye, E.O., Early detection of tumor response to chemotherapy by 3′-deoxy- 3′-(18F)fluorothymidine positron emission tomography: The effect of cisplatin on a fibrosarcoma tumor model in vivo (2005) Cancer Res, 65, pp. 4202-4210
Barthel, H., Cleij, M.C., Collingridge, D.R., Hutchinson, O.C., Osman, S., He, Q., Luthra, S.K., Aboagye, E.O., 3′-deoxy- 3′-(18F)fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography (2003) Cancer Res, 63, pp. 3791-3798
Perumal, M., Pillai, R.G., Barthel, H., Leyton, J., Latigo, J.R., Forster, M., Mitchell, F., Aboagye, E.O., Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography (2006) Cancer Res, 66, pp. 8558-8564
Buck, A.K., Kratochwil, C., Glatting, G., Juweid, M., Bommer, M., Tepsic, D., Vogg, A.T.J., Reske, S.N., Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT (2007) European Journal of Nuclear Medicine and Molecular Imaging, 34 (11), pp. 1775-1782. , DOI 10.1007/s00259-007-0452-z
Graf, N., Herrmann, K., Den Hollander, J., Fend, F., Schuster, T., Wester, H.J., Senekowitsch-Schmidtke, R., Buck, A.K., Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment (2008) Mol Imag Biol, 10, pp. 349-355
Leyton, J., Alao, J.P., Da Costa, M., Stavropoulou, A.V., Latigo, J.R., Perumal, M., Pillai, R., Aboagye, E.O., In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3′-deoxy-3′-(18F)fluorothymidine positron emission tomography (2006) Cancer Res, 66, pp. 7621-7629
Waldherr, C., Mellinghoff, I.K., Tran, C., Halpern, B.S., Rozengurt, N., Safaei, A., Weber, W.A., Czernin, J., Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′-18F-fluorothymidine PET (2005) J Nucl Med, 46, pp. 114-120
Ullrich, R.T., Zander, T., Neumaier, B., Koker, M., Shimamura, T., Waerzeggers, Y., Borgman, C.L., Winkeler, A., Early detection of erlotinib treatment response in NSCLC by 3′-deoxy-3′-(F)-fluoro-L-thymidine ((F)FLT) positron emission tomography (PET) (2008) PLoS ONE, 3, pp. e3908
Leyton, J., Smith, G., Lees, M., Perumal, M., Nguyen, Q.D., Aigbirhio, F.I., Golovko, O., Aboagye, E.O., Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901 (2008) Mol Cancer Ther, 7, pp. 3112-3121
Chen, W., Delaloye, S., Silverman, D.H., Geist, C., Czernin, J., Sayre, J., Satyamurthy, N., Cloughesy, T., Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with (18F) fluorothymidine positron emission tomography: A pilot study (2007) J Clin Oncol, 25, pp. 4714-4721
Herrmann, K., Wieder, H.A., Buck, A.K., Schoffel, M., Krause, B.J., Fend, F., Schuster, T., Dechow, T., Early response assessment using 3′-deoxy-3′-( 18F)fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma (2007) Clin Cancer Res, 13, pp. 3552-3558
Kenny, L., Coombes, R.C., Vigushin, D.M., Al-Nahhas, A., Shousha, S., Aboagye, E.O., Imaging early changes in proliferation at 1 week post chemotherapy: A pilot study in breast cancer patients with 3′-deoxy-3′-( 18F)fluorothymidine positron emission tomography (2007) Eur J Nucl Med Mol Imag, 34, pp. 1339-1347
Wieder, H.A., Geinitz, H., Rosenberg, R., Lordick, F., Becker, K., Stahl, A., Rummeny, E., Stollfuss, J., PET imaging with (18F)3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer (2007) Eur J Nucl Med Mol Imag, 34, pp. 878-883
Herbst, R.S., Fukuoka, M., Baselga, J., Gefitinib - A novel targeted approach to treating cancer (2004) Nat Rev Cancer, 4, pp. 956-965
Cai, W., Niu, G., Chen, X., Multimodality imaging of the HER-kinase axis in cancer (2008) Eur J Nucl Med Mol Imag, 35, pp. 186-208
Perk, L.R., Visser, G.W., Vosjan, M.J., Stigter-van Walsum, M., Tijink, B.M., Leemans, C.R., Van Dongen, G.A., (89)Zr as a PET surrogate radio-isotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab (2005) J Nucl Med, 46, pp. 1898-1906
Cai, W., Chen, K., He, L., Cao, Q., Koong, A., Chen, X., Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody (2007) Eur J Nucl Med Mol Imag, 34, pp. 850-858
Aerts, H.J., Dubois, L., Perk, L., Vermaelen, P., Van Dongen, G.A., Wouters, B.G., Lambin, P., Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET (2009) J Nucl Med, 50, pp. 123-131
Velikyan, I., Sundberg, A.L., Lindhe, O., Hoglund, A.U., Eriksson, O., Werner, E., Carlsson, J., Tolmachev, V., Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors (2005) J Nucl Med, 46, pp. 1881-1888
Bonasera, T.A., Ortu, G., Rozen, Y., Krais, R., Freedman, N.M., Chisin, R., Gazit, A., Mishani, E., Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase (2001) Nucl Med Biol, 28, pp. 359-374
Ortu, G., Ben-David, I., Rozen, Y., Freedman, N.M., Chisin, R., Levitzki, A., Mishani, E., Labeled EGFr-TK irreversible inhibitor (ML03): In vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug (2002) Int J Cancer, 101, pp. 360-370
Pal, A., Glekas, A., Doubrovin, M., Balatoni, J., Namavari, M., Beresten, T., Maxwell, D., Gelovani, J.G., Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography (2006) Mol Imag Biol, 8, pp. 262-877
Mishani, E., Abourbeh, G., Jacobson, O., Dissoki, S., Ben Daniel, R., Rozen, Y., Shaul, M., Levitzki, A., High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors (2005) J Med Chem, 48, pp. 5337-5348
Abourbeh, G., Dissoki, S., Jacobson, O., Litchi, A., Ben Daniel, R., Laki, D., Levitzki, A., Mishani, E., Evaluation of radiolabeled ML04:A putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors (2007) Nucl Med Biol, 34, pp. 55-70
Wang, J.Q., Gao, M., Miller, K.D., Sledge, G.W., Zheng, Q.H., Synthesis of (11C)Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase (2006) Bioorg Med Chem Lett, 16, pp. 4102-4106
Memon, A.A., Jakobsen, S., Dagnaes-Hansen, F., Sorensen, B.S., Keiding, S., Nexo, E., Positron emission tomography (PET) imaging with (11C)-labeled erlotinib: A micro-PET study on mice with lung tumor xenografts (2009) Cancer Res, 69, pp. 873-878
Seimbille, Y., Phelps, M.E., Czernin, J., Silverman, D.S., Fluorin-18 labeling of 6,7-distributed anilinoquinazoline derivates, for positron emission tomography (PET) imaging of tyrosine kinase receptors: Syntesis of18F-Iressa and related molecular probes (2005) J Label Compd Radiopharm, 48, pp. 829-843
Su, H., Seimbille, Y., Ferl, G.Z., Bodenstein, C., Fueger, B., Kim, K.J., Hsu, Y.T., Weber, W.A., Evaluation of ((18)F)gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors (2008) Eur J Nucl Med Mol Imag, 35, pp. 1089-1099
Liu, N., Li, M., Li, X., Meng, X., Yang, G., Zhao, S., Yang, Y., Yu, J., PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer11C-PD153035 in humans (2009) J Nucl Med, 50, pp. 303-308
Fredriksson, A., Johnstrom, P., Thorell, J.O., Von Heijne, G., Hassan, M., Eksborg, S., Kogner, P., Stone-Elander, S., In vivo evaluation of the biodistribution of11C-labeled PD153035 in rats without and with neuroblastoma implants (1999) Life Sci, 65, pp. 165-174
Sergina, N.V., Moasser, M.M., The HER family and cancer: Emerging molecular mechanisms and therapeutic targets (2007) Trends in Molecular Medicine, 13 (12), pp. 527-534. , DOI 10.1016/j.molmed.2007.10.002, PII S1471491407001864
Di Cosimo, S., Baselga, J., Targeted therapies in breast cancer: Where are we now? (2008) Eur J Cancer, 44, pp. 2781-2790
Nielsen, D.L., Andersson, M., Kamby, C., HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors (2009) Cancer Treat Rev, 35, pp. 121-136
Dean-Colomb, W., Esteva, F.J., Her2-positive breast cancer: Herceptin and beyond (2008) Eur J Cancer, 44, pp. 2806-2812
Robinson, M.K., Doss, M., Shaller, C., Narayanan, D., Marks, J.D., Adler, L.P., De Trotter, G., Adams, G.P., Quantitative immunopositron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody (2005) Cancer Res, 65, pp. 1471-1478
Olafsen, T., Kenanova, V.E., Sundaresan, G., Anderson, A.L., Crow, D., Yazaki, P.J., Li, L., Wu, A.M., Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging (2005) Cancer Res, 65, pp. 5907-5916
Garmestani, K., Milenic, D.E., Plascjak, P.S., Brechbiel, M.W., A new and convenient method for purification of86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111in labeled Herceptin (2002) Nucl Med Biol, 29, pp. 599-606
Smith-Jones, P.M., Solit, D.B., Akhurst, T., Afroze, F., Rosen, N., Larson, S.M., Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors (2004) Nat Biotechnol, 22, pp. 701-706
Tolmachev, V., Imaging of HER-2 overexpression in tumors for guiding therapy (2008) Curr Pharm des, 14, pp. 2999-3019
Orlova, A., Wallberg, H., Stone-Elander, S., Tolmachev, V., On the selection of a tracer for PET imaging of HER2-expressing tumors: Direct comparison of a124I-labeled affibody molecule and trastuzumab in a murine xenograft model (2009) J Nucl Med, 50, pp. 417-425
Cheng, Z., De Jesus, O.P., Namavari, M., De, A., Levi, J., Webster, J.M., Zhang, R., Gambhir, S.S., Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific18F-labeled protein scaffold molecules (2008) J Nucl Med, 49, pp. 804-813
Chen, X., Conti, P.S., Moats, R.A., In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts (2004) Cancer Res, 64, pp. 8009-8014
Sipkins, D.A., Cheresh, D.A., Kazemi, M.R., Nevin, L.M., Bednarski, M.D., Li, K.C., Detection of tumor angiogenesis in vivo by alphaVbeta3- targeted magnetic resonance imaging (1998) Nat Med, 4, pp. 623-626
Zhang, C., Jugold, M., Woenne, E.C., Lammers, T., Morgenstern, B., Mueller, M.M., Zentgraf, H., Kiessling, F., Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner (2007) Cancer Res, 67, pp. 1555-1562
Ellegala, D.B., Leong-Poi, H., Carpenter, J.E., Klibanov, A.L., Kaul, S., Shaffrey, M.E., Sklenar, J., Lindner, J.R., Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3 (2003) Circulation, 108, pp. 336-341
Janssen, M.L., Oyen, W.J., Dijkgraaf, I., Massuger, L.F., Frielink, C., Edwards, D.S., Rajopadhye, M., Boerman, O.C., Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model (2002) Cancer Res, 62, pp. 6146-6151
Haubner, R., Wester, H.J., Weber, W.A., Mang, C., Ziegler, S.I., Goodman, S.L., Senekowitsch-Schmidtke, R., Schwaiger, M., Non-invasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography (2001) Cancer Res, 61, pp. 1781-1785
Chen, X., Hou, Y., Tohme, M., Park, R., Khankaldyyan, V., Gonzales-Gomez, I., Bading, J.R., Conti, P.S., Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression (2004) J Nucl Med, 45, pp. 1776-1783
Cai, W., Wu, Y., Chen, K., Cao, Q., Tice, D.A., Chen, X., In vitro and in vivo characterization of64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3 (2006) Cancer Res, 66, pp. 9673-9681
Haubner, R., Weber, W.A., Beer, A.J., Vabuliene, E., Reim, D., Sarbia, M., Becker, K.F., Schwaiger, M., Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and (18F)Galacto-RGD (2005) PLoS Med, 2, p. 70
Beer, A.J., Haubner, R., Sarbia, M., Goebel, M., Luderschmidt, S., Grosu, A.L., Schnell, O., Schwaiger, M., Positron emission tomography using (18F)Galacto- RGD identifies the level of integrin alpha(v)beta3 expression in man (2006) Clin Cancer Res, 12, pp. 3942-3949
Beer, A.J., Grosu, A.L., Carlsen, J., Kolk, A., Sarbia, M., Stangier, I., Watzlowik, P., Schwaiger, M., (18F)galacto- RGD positron emission tomography for imaging of alphav-beta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck (2007) Clin Cancer Res, 13, pp. 6610-6616
Beer, A.J., Niemeyer, M., Carlsen, J., Sarbia, M., Nahrig, J., Watzlowik, P., Wester, H.J., Schwaiger, M., Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by18F-Galacto-RGD PET (2008) J Nucl Med, 49, pp. 255-259
Zannetti, A., Del Vecchio, S., Iommelli, F., Del Gatto, A., De Luca, S., Zaccaro, L., Papaccioli, A., Salvatore, M., Imaging of alphavbeta3 expression by a bifunctional chimeric RGD peptide not cross-reacting with alphavbeta5 (2009) Clin Cancer Res, 15, pp. 5224-5233
Wu, Y., Zhang, X., Xiong, Z., Cheng, Z., Fisher, D.R., Liu, S., Gambhir, S.S., Chen, X., MicroPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide (2005) J Nucl Med, 46, pp. 1707-1718
Kenny, L.M., Coombes, R.C., Oulie, I., Contractor, K.B., Miller, M., Spinks, T.J., McParland, B., Aboagye, E.O., Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand18F-AH111585 in breast cancer patients (2008) J Nucl Med, 49, pp. 879-886
Chen, X., Park, R., Hou, Y., Khankaldyyan, V., Gonzales-Gomez, I., Tohme, M., Bading, J.R., Conti, P.S., MicroPET imaging of brain tumor angiogenesis with18F-labeled PEGylated RGD peptide (2004) Eur J Nucl Med Mol Imag, 31, pp. 1081-1089
Waxman, D.J., Schwartz, P.S., Harnessing Apoptosis for Improved Anticancer Gene Therapy (2003) Cancer Research, 63 (24), pp. 8563-8572
Blankenberg, F.G., In vivo imaging of apoptosis (2008) Cancer Biol Ther, 7, pp. 1525-1532
Yagle, K.J., Eary, J.F., Tait, J.F., Grierson, J.R., Link, J.M., Lewellen, B., Gibson, D.F., Krohn, K.A., Evaluation of18F-annexin V as a PET imaging agent in an animal model of apoptosis (2005) J Nucl Med, 46, pp. 658-866
Dekker, B., Keen, H., Lyons, S., Disley, L., Hastings, D., Reader, A., Ottewell, P., Zweit, J., MBP-annexin V radiolabeled directly with iodine-124 can be used to image apoptosis in vivo using PET (2005) Nucl Med Biol, 32, pp. 241-252
Keen, H.G., Dekker, B.A., Disley, L., Hastings, D., Lyons, S., Reader, A.J., Ottewell, P., Zweit, J., Imaging apoptosis in vivo using124I-annexin V and PET (2005) Nucl Med Biol, 32, pp. 395-402
Cauchon, N., Langlois, R., Rousseau, J.A., Tessier, G., Cadorette, J., Lecomte, R., Hunting, D.J., Van Lier, J.E., PET imaging of apoptosis with (64)Cu-labeled streptavidin following pretargeting of phosphatidylserine with biotinylated annexin-V (2007) Eur J Nucl Med Mol Imag, 34, pp. 247-258
Gottlieb, R.A., Kitsis, R.N., Seeing death in the living (2001) Nat Med, 7, pp. 1277-1278
Brouckaert, G., Kalai, M., Krysko, D.V., Saelens, X., Vercammen, D., Ndlovu, M., Haegeman, G., Vandenabeele, P., Phagocytosis of necrotic cells by macrophages is phosphatidylserine dependent and does not induce inflammatory cytokine production (2004) Mol Biol Cell, 15, pp. 1089-1100
Lee, D., Long, S.A., Adams, J.L., Chan, G., Vaidya, K.S., Francis, T.A., Kikly, K., Nuttall, M.E., Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality (2000) J Biol Chem, 275, pp. 16007-16014
Nguyen, Q.D., Smith, G., Glaser, M., Perumal, M., Arstad, E., Aboagye, E.O., Positron Emission tomography imaging of drug-induced apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide (2009) Proc Natl Acad Sci USA, 106, pp. 16375-16380
Zhou, D., Chu, W., Chen, D.L., Wang, Q., Reichert, D.E., Rothfuss, J., D'Avignon, A., Mach, R.H., (18F)- and (11C)-labeled N-benzyl-isatin sulfonamide analogues as PET tracers for apoptosis: Synthesis, radiolabeling mechanism, and in vivo imaging study of apoptosis in Fas-treated mice using (11C)WC-98 (2009) Org Biomol Chem, 7, pp. 1337-1348
Madar, I., Ravert, H., Nelkin, B., Abro, M., Pomper, M., Dannals, R., Frost, J.J., Characterization of membrane potential-dependent uptake of the novel PET tracer18F-fluorobenzyl triphenylphosphonium cation (2007) Eur J Nucl Med Mol Imag, 34, pp. 2057-2065
Aloya, R., Shirvan, A., Grimberg, H., Reshef, A., Levin, G., Kidron, D., Cohen, A., Ziv, I., Molecular imaging of cell death in vivo by a novel small molecule probe (2006) Apoptosis, 11, pp. 2089-2101
Zeng, W., Yao, M.L., Townsend, D., Kabalka, G., Wall, J., Le Puil, M., Biggerstaff, J., Miao, W., Synthesis, biological evaluation and radiochemical labeling of a dansylhydrazone derivative as a potential imaging agent for apoptosis (2008) Bioorg Med Chem Lett, 18, pp. 3573-3577
Reshef, A., Shirvan, A., Waterhouse, R.N., Grimberg, H., Levin, G., Cohen, A., Ulysse, L.G., Ziv, I., Molecular imaging of neurovascular cell death in experimental cerebral stroke by PET (2008) J Nucl Med, 49, pp. 1520-1528
Shirvan, A., Reshef, A., Allen, A., Fenig, E., Steinmetz, A., Groshar, D., Mishani, E., Ziv, I., Apoptosis imaging with PET-18F-ML-10 for early assessment of response of brain metastases to radiotherapy (2009) J Nucl Med, 50, p. 43
Scherer, R.L., McIntyre, J.O., Matrisian, L.M., Imaging matrix metalloproteinases in cancer (2008) Cancer Metastasis Rev, 27, pp. 679-690
Furumoto, S., Takashima, K., Kubota, K., Ido, T., Iwata, R., Fukuda, H., Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor (2003) Nucl Med Biol, 30, pp. 119-125
Zheng, Q.H., Fei, X., Liu, X., Wang, J.Q., Sun, B., Mock, H., Lee, B.H., Hutchins, G.D., Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers (11C)methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents (2002) Nucl Med Biol, 29, pp. 761-770
Wagner, S., Breyholz, H.J., Holtke, C., Faust, A., Schober, O., Schafers, M., Kopka, K., A new 18F-labelled derivative of the MMP inhibitor CGS 27023A for PET: Radiosynthesis and initial small-animal PET studies (2009) Appl Radiat Isot, 67, pp. 606-610
D'Alessio, S., Blasi, F., The urokinase receptor as an entertainer of signal transduction (2009) Front Biosci, 14, pp. 4575-4587
Dass, K., Ahmad, A., Azmi, A.S., Sarkar, S.H., Sarkar, F.H., Evolving role of uPA/uPAR system in human cancers (2008) Cancer Treat Rev, 34, pp. 122-136
Del Vecchio, S., Stoppelli, M.P., Carriero, M.V., Fonti, R., Massa, O., Li, P.Y., Botti, G., Esposito, G., Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: Comparison with urokinase levels (1993) Cancer Res, 53, pp. 3198-3206
Mohanam, S., Chintala, S.K., Go, Y., Bhattacharya, A., Venkaiah, B., Boyd, D., Gokaslan, Z.L., Rao, J.S., In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor (1997) Oncogene, 14, pp. 1351-1359
Rabbani, S.A., Gladu, J., Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo (2002) Cancer Research, 62 (8), pp. 2390-2397
Subramanian, R., Gondi, C.S., Lakka, S.S., Jutla, A., Rao, J.S., SiRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells (2006) Int J Oncol, 28, pp. 831-839
Li, Z.B., Niu, G., Wang, H., He, L., Yang, L., Ploug, M., Chen, X., Imaging of urokinase-type plasminogen activator receptor expression using a64Cu-labeled linear peptide antagonist by microPET (2008) Clin Cancer Res, 14, pp. 4758-4766
Albelda, S.M., Mette, S.A., Elder, D.E., Stewart, R., Damjanovich, L., Herlyn, M., Buck, C.A., Integrin distribution in malignant melanoma: Association of the beta 3 subunit with tumor progression (1990) Cancer Res, 50, pp. 6757-6764
Schnell, O., Krebs, B., Wagner, E., Romagna, A., Beer, A.J., Grau, S.J., Thon, N., Goldbrunner, R.H., Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature (2008) Brain Pathol, 18, pp. 378-386
Liapis, H., Adler, L.M., Wick, M.R., Rader, J.S., Expression of alpha(v)- beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas (1997) Hum Pathol, 28, pp. 443-449
Gasparini, G., Brooks, P.C., Biganzoli, E., Vermeulen, P.B., Bonoldi, E., Dirix, L.Y., Ranieri, G., Cheresh, D.A., Vascular integrin alpha(v)beta3: A new prognostic indicator in breast cancer (1998) Clin Cancer Res, 4, pp. 2625-2634
Felding-Habermann, B., O'Toole, T.E., Smith, J.W., Fransvea, E., Ruggeri, Z.M., Ginsberg, M.H., Hughes, P.E., Mueller, B.M., Integrin activation controls metastasis in human breast cancer (2001) Proc Natl Acad Sci USA, 98, pp. 1853-1858
Rolli, M., Fransvea, E., Pilch, J., Saven, A., Felding-Habermann, B., Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells (2003) Proceedings of the National Academy of Sciences of the United States of America, 100 (16), pp. 9482-9487. , DOI 10.1073/pnas.1633689100
Carriero, M.V., Del Vecchio, S., Capozzoli, M., Franco, P., Fontana, L., Zannetti, A., Botti, G., Stoppelli, M.P., Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer (1999) Cancer Res, 59, pp. 5307-5314
Beer, A.J., Schwaiger, M., Imaging of integrin alphavbeta3 expression (2008) Cancer Metastasis Rev, 27, pp. 631-644
Koizumi, K., Hojo, S., Akashi, T., Yasumoto, K., Saiki, I., Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response (2007) Cancer Sci, 98, pp. 1652-1658
Jacobson, O., Weiss, I.D., Szajek, L., Farber, J.M., Kiesewetter, D.O., 64Cu-AMD3100 - A novel imaging agent for targeting chemokine receptor CXCR4 (2009) Bioorg Med Chem, 17, pp. 1486-1493
Fletcher, J.W., Djulbegovic, B., Soares, H.P., Siegel, B.A., Lowe, V.J., Lyman, G.H., Coleman, R.E., Shields, A.F., Recommendations on the use of18F-FDG PET in oncology (2008) J Nucl Med, 49, pp. 480-508
Mawlawi, O., Townsend, D.W., Multimodality imaging: An update on PET/CT technology (2009) Eur J Nucl Med Mol Imag, 36 (SUPPL. 1), pp. S15-29
Plathow, C., Weber, W.A., Tumor cell metabolism imaging (2008) J Nucl Med, 49 (SUPPL. 2), pp. 43S-63S
Kim, J.W., Dang, C.V., Cancer's molecular sweet tooth and the Warburg effect (2006) Cancer Res, 66, pp. 8927-8930
Gillies, R.J., Robey, I., Gatenby, R.A., Causes and consequences of increased glucose metabolism of cancers (2008) J Nucl Med, 49 (SUPPL. 2), pp. 24S-42S
Townsend, D.W., Dual-modality imaging: Combining anatomy and function (2008) J Nucl Med, 49, pp. 938-955
Ben-Haim, S., Ell, P., 18F-FDG PET and PET/CT in the evaluation of cancer treatment response (2009) J Nucl Med, 50, pp. 88-99
Hutchings, M., Barrington, S.F., PET/CT for therapy response assessment in lymphoma (2009) J Nucl Med, 50 (SUPPL.), pp. 21S-30S
Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Diehl, V., Revised response criteria for malignant lymphoma (2007) J Clin Oncol, 25, pp. 579-586
Wahl, R.L., Jacene, H., Kasamon, Y., Lodge, M.A., From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors (2009) J Nucl Med, 50 (SUPPL. 1), pp. 122S-a50S
Vriens, D., De Geus-Oei, L.F., Van Der Graaf, W.T.A., Oyen, W.J.G., Tailoring therapy in colorectal cancer by PET-CT (2009) Q J Nucl Med Mol Imag, 53, pp. 224-244
Chuang, H.H., Macapinlac, H.A., The evolving role of PET-CT in the management of esophageal cancer (2009) Q J Nucl Med Mol Imag, 53, pp. 201-209
Hichs, R., Role of18F-FDG PET in assessment of response in non-small cell lung cancer (2009) J Nucl Med, 50 (SUPPL.), pp. 31S-42S
Pons, F., Duch, J., Fuster, D., Breast cancer therapy: The role of PET-CT in decision making (2009) Q J Nucl Med Mol Imag, 53, pp. 210-223
Lordick, F., Ott, K., Krause, B.J., Weber, W.A., Becker, K., Stein, H.J., Lorenzen, S., Siewert, J.R., PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial (2007) Lancet Oncol, 8, pp. 797-805
Delso, G., Ziegler, S., PET/MRI system design (2009) Eur J Nucl Med Mol Imag, 36 (SUPPL. 1), pp. S86-92
Pichler, B.J., Wehrl, H.F., Judenhofer, M.S., Latest advances in molecular imaging instrumentation (2008) J Nucl Med, 49 (SUPPL. 2), pp. 5S-23S
Kang, J. H., Chung, J. K., Molecular-genetic imaging based on reporter gene expression (2008) J Nucl Med, 49 (SUPPL. 2), pp. 164S-179S
Bading, J. R., Shields, A. F., Imaging of cell proliferation: Status and prospects (2008) J Nucl Med, 49 (SUPPL. 2), pp. 64S-80S
Buck, A. K., Schirrmeister, H., Hetzel, M., Von Der Heide, M., Halter, G., Glatting, G., Mattfeldt, T., Neumaier, B., 3-deoxy-3- ((18) F) fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules (2002) Cancer Res, 62, pp. 3331-3334
Buck, A. K., Halter, G., Schirrmeister, H., Kotzerke, J., Wurziger, I., Glatting, G., Mattfeldt, T., Hetzel, M., Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG (2003) J Nucl Med, 44, pp. 1426-1431
Buck, A. K., Hetzel, M., Schirrmeister, H., Halter, G., Moller, P., Kratochwil, C., Wahl, A., Reske, S. N., Clinical relevance of imaging proliferative activity in lung nodules (2005) Eur J Nucl Med Mol Imag, 32, pp. 525-533
Yap, C. S., Czernin, J., Fishbein, M. C., Cameron, R. B., Schiepers, C., Phelps, M. E., Weber, W. A., Evaluation of thoracic tumors with18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography (2006) Chest, 129, pp. 393-401
Van Westreenen, H. L., Cobben, D. C., Jager, P. L., Van Dullemen, H. M., Wesseling, J., Elsinga, P. H., Plukker, J. T., Comparison of18F-FLT PET and18F-FDG PET in esophageal cancer (2005) J Nucl Med, 46, pp. 400-404
Francis, D. L., Visvikis, D., Costa, D. C., Arulampalam, T. H., Townsend, C., Luthra, S. K., Taylor, I., Ell, P. J., Potential impact of (18F) 3 -deoxy- 3 - fluorothymidine versus (18F) fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer (2003) Eur J Nucl Med Mol Imag, 30, pp. 988-994
Jacobs, A. H., Thomas, A., Kracht, L. W., Li, H., Dittmar, C., Garlip, G., Galldiks, N., Heiss, W. D., 18F-fluoro-L-thymidine and11C-methylmethionine as markers of increased transport and proliferation in brain tumors (2005) J Nucl Med, 46, pp. 1948-1958
Choi, S. J., Kim, J. S., Kim, J. H., Oh, S. J., Lee, J. G., Kim, C. J., Ra, Y. S., Moon, D. H., (18F) 3 -deoxy-3 -fluorothymidine PET for the diagnosis and grading of brain tumors (2005) Eur J Nucl Med Mol Imag, 32, pp. 653-659
Kenny, L. M., Vigushin, D. M., Al-Nahhas, A., Osman, S., Luthra, S. K., Shousha, S., Coombes, R. C., Aboagye, E. O., Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by (18F) fluorothymidine-positron emission tomography imaging: Evaluation of analytical methods (2005) Cancer Res, 65, pp. 10104-11012
Buck, A. K., Kratochwil, C., Glatting, G., Juweid, M., Bommer, M., Tepsic, D., Vogg, A. T. J., Reske, S. N., Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F] FLT (2007) European Journal of Nuclear Medicine and Molecular Imaging, 34 (11), pp. 1775-1782. , DOI 10. 1007/s00259-007-0452-z
Ullrich, R. T., Zander, T., Neumaier, B., Koker, M., Shimamura, T., Waerzeggers, Y., Borgman, C. L., Winkeler, A., Early detection of erlotinib treatment response in NSCLC by 3 -deoxy-3 - (F) -fluoro-L-thymidine ((F) FLT) positron emission tomography (PET) (2008) PLoS ONE, 3, pp. e3908
Wieder, H. A., Geinitz, H., Rosenberg, R., Lordick, F., Becker, K., Stahl, A., Rummeny, E., Stollfuss, J., PET imaging with (18F) 3 -deoxy-3 -fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer (2007) Eur J Nucl Med Mol Imag, 34, pp. 878-883
Herbst, R. S., Fukuoka, M., Baselga, J., Gefitinib - A novel targeted approach to treating cancer (2004) Nat Rev Cancer, 4, pp. 956-965
Perk, L. R., Visser, G. W., Vosjan, M. J., Stigter-van Walsum, M., Tijink, B. M., Leemans, C. R., Van Dongen, G. A., (89) Zr as a PET surrogate radio-isotope for scouting biodistribution of the therapeutic radiometals (90) Y and (177) Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab (2005) J Nucl Med, 46, pp. 1898-1906
Aerts, H. J., Dubois, L., Perk, L., Vermaelen, P., Van Dongen, G. A., Wouters, B. G., Lambin, P., Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET (2009) J Nucl Med, 50, pp. 123-131
Bonasera, T. A., Ortu, G., Rozen, Y., Krais, R., Freedman, N. M., Chisin, R., Gazit, A., Mishani, E., Potential (18) F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase (2001) Nucl Med Biol, 28, pp. 359-374
Wang, J. Q., Gao, M., Miller, K. D., Sledge, G. W., Zheng, Q. H., Synthesis of (11C) Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase (2006) Bioorg Med Chem Lett, 16, pp. 4102-4106
Memon, A. A., Jakobsen, S., Dagnaes-Hansen, F., Sorensen, B. S., Keiding, S., Nexo, E., Positron emission tomography (PET) imaging with (11C) -labeled erlotinib: A micro-PET study on mice with lung tumor xenografts (2009) Cancer Res, 69, pp. 873-878
Sergina, N. V., Moasser, M. M., The HER family and cancer: Emerging molecular mechanisms and therapeutic targets (2007) Trends in Molecular Medicine, 13 (12), pp. 527-534. , DOI 10. 1016/j. molmed. 2007. 10. 002, PII S1471491407001864
Nielsen, D. L., Andersson, M., Kamby, C., HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors (2009) Cancer Treat Rev, 35, pp. 121-136
Robinson, M. K., Doss, M., Shaller, C., Narayanan, D., Marks, J. D., Adler, L. P., De Trotter, G., Adams, G. P., Quantitative immunopositron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody (2005) Cancer Res, 65, pp. 1471-1478
Smith-Jones, P. M., Solit, D. B., Akhurst, T., Afroze, F., Rosen, N., Larson, S. M., Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors (2004) Nat Biotechnol, 22, pp. 701-706
Sipkins, D. A., Cheresh, D. A., Kazemi, M. R., Nevin, L. M., Bednarski, M. D., Li, K. C., Detection of tumor angiogenesis in vivo by alphaVbeta3- targeted magnetic resonance imaging (1998) Nat Med, 4, pp. 623-626
Ellegala, D. B., Leong-Poi, H., Carpenter, J. E., Klibanov, A. L., Kaul, S., Shaffrey, M. E., Sklenar, J., Lindner, J. R., Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha (v) beta3 (2003) Circulation, 108, pp. 336-341
Janssen, M. L., Oyen, W. J., Dijkgraaf, I., Massuger, L. F., Frielink, C., Edwards, D. S., Rajopadhye, M., Boerman, O. C., Tumor targeting with radiolabeled alpha (v) beta (3) integrin binding peptides in a nude mouse model (2002) Cancer Res, 62, pp. 6146-6151
Beer, A. J., Haubner, R., Sarbia, M., Goebel, M., Luderschmidt, S., Grosu, A. L., Schnell, O., Schwaiger, M., Positron emission tomography using (18F) Galacto- RGD identifies the level of integrin alpha (v) beta3 expression in man (2006) Clin Cancer Res, 12, pp. 3942-3949
Beer, A. J., Grosu, A. L., Carlsen, J., Kolk, A., Sarbia, M., Stangier, I., Watzlowik, P., Schwaiger, M., (18F) galacto- RGD positron emission tomography for imaging of alphav-beta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck (2007) Clin Cancer Res, 13, pp. 6610-6616
Beer, A. J., Niemeyer, M., Carlsen, J., Sarbia, M., Nahrig, J., Watzlowik, P., Wester, H. J., Schwaiger, M., Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by18F-Galacto-RGD PET (2008) J Nucl Med, 49, pp. 255-259
Kenny, L. M., Coombes, R. C., Oulie, I., Contractor, K. B., Miller, M., Spinks, T. J., McParland, B., Aboagye, E. O., Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand18F-AH111585 in breast cancer patients (2008) J Nucl Med, 49, pp. 879-886
Waxman, D. J., Schwartz, P. S., Harnessing Apoptosis for Improved Anticancer Gene Therapy (2003) Cancer Research, 63 (24), pp. 8563-8572
Blankenberg, F. G., In vivo imaging of apoptosis (2008) Cancer Biol Ther, 7, pp. 1525-1532
Yagle, K. J., Eary, J. F., Tait, J. F., Grierson, J. R., Link, J. M., Lewellen, B., Gibson, D. F., Krohn, K. A., Evaluation of18F-annexin V as a PET imaging agent in an animal model of apoptosis (2005) J Nucl Med, 46, pp. 658-866
Keen, H. G., Dekker, B. A., Disley, L., Hastings, D., Lyons, S., Reader, A. J., Ottewell, P., Zweit, J., Imaging apoptosis in vivo using124I-annexin V and PET (2005) Nucl Med Biol, 32, pp. 395-402
Gottlieb, R. A., Kitsis, R. N., Seeing death in the living (2001) Nat Med, 7, pp. 1277-1278
Lee, D., Long, S. A., Adams, J. L., Chan, G., Vaidya, K. S., Francis, T. A., Kikly, K., Nuttall, M. E., Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality (2000) J Biol Chem, 275, pp. 16007-16014
Nguyen, Q. D., Smith, G., Glaser, M., Perumal, M., Arstad, E., Aboagye, E. O., Positron Emission tomography imaging of drug-induced apoptosis with a caspase-3/7 specific [18F] -labeled isatin sulfonamide (2009) Proc Natl Acad Sci USA, 106, pp. 16375-16380
Zeng, W., Yao, M. L., Townsend, D., Kabalka, G., Wall, J., Le Puil, M., Biggerstaff, J., Miao, W., Synthesis, biological evaluation and radiochemical labeling of a dansylhydrazone derivative as a potential imaging agent for apoptosis (2008) Bioorg Med Chem Lett, 18, pp. 3573-3577
Scherer, R. L., McIntyre, J. O., Matrisian, L. M., Imaging matrix metalloproteinases in cancer (2008) Cancer Metastasis Rev, 27, pp. 679-690
Zheng, Q. H., Fei, X., Liu, X., Wang, J. Q., Sun, B., Mock, H., Lee, B. H., Hutchins, G. D., Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers (11C) methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents (2002) Nucl Med Biol, 29, pp. 761-770
Rabbani, S. A., Gladu, J., Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo (2002) Cancer Research, 62 (8), pp. 2390-2397
Li, Z. B., Niu, G., Wang, H., He, L., Yang, L., Ploug, M., Chen, X., Imaging of urokinase-type plasminogen activator receptor expression using a64Cu-labeled linear peptide antagonist by microPET (2008) Clin Cancer Res, 14, pp. 4758-4766
Albelda, S. M., Mette, S. A., Elder, D. E., Stewart, R., Damjanovich, L., Herlyn, M., Buck, C. A., Integrin distribution in malignant melanoma: Association of the beta 3 subunit with tumor progression (1990) Cancer Res, 50, pp. 6757-6764
Carriero, M. V., Del Vecchio, S., Capozzoli, M., Franco, P., Fontana, L., Zannetti, A., Botti, G., Stoppelli, M. P., Urokinase receptor interacts with alpha (v) beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer (1999) Cancer Res, 59, pp. 5307-5314
Beer, A. J., Schwaiger, M., Imaging of integrin alphavbeta3 expression (2008) Cancer Metastasis Rev, 27, pp. 631-644
Fletcher, J. W., Djulbegovic, B., Soares, H. P., Siegel, B. A., Lowe, V. J., Lyman, G. H., Coleman, R. E., Shields, A. F., Recommendations on the use of18F-FDG PET in oncology (2008) J Nucl Med, 49, pp. 480-508
Kim, J. W., Dang, C. V., Cancer's molecular sweet tooth and the Warburg effect (2006) Cancer Res, 66, pp. 8927-8930
Gillies, R. J., Robey, I., Gatenby, R. A., Causes and consequences of increased glucose metabolism of cancers (2008) J Nucl Med, 49 (SUPPL. 2), pp. 24S-42S
Townsend, D. W., Dual-modality imaging: Combining anatomy and function (2008) J Nucl Med, 49, pp. 938-955
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Diehl, V., Revised response criteria for malignant lymphoma (2007) J Clin Oncol, 25, pp. 579-586
Wahl, R. L., Jacene, H., Kasamon, Y., Lodge, M. A., From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors (2009) J Nucl Med, 50 (SUPPL. 1), pp. 122S-a50S
Chuang, H. H., Macapinlac, H. A., The evolving role of PET-CT in the management of esophageal cancer (2009) Q J Nucl Med Mol Imag, 53, pp. 201-209
Pichler, B. J., Wehrl, H. F., Judenhofer, M. S., Latest advances in molecular imaging instrumentation (2008) J Nucl Med, 49 (SUPPL. 2), pp. 5S-23S
Contrast Media Mol Imaging (ISSN: 1555-4309, 1555-4309linking), 2010 Jul; 5(4): 190-200.
Export to BibTeX Export to EndNote
Paper type: Journal Article, Review,
Impact factor: 4.02, 5-year impact factor: 4.149
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-77956139255&partnerID=40&md5=fc9f8842f054a65507ace506d3efbe67
Keywords: Cancer, Pet Ct, Translational Research, Fluorothymidine F 18, 4 (3 Bromoanilino) 6, 7 Dimethoxyquinazoline, 6 (4 Hydroxyphenyl) 4 (alpha Methylbenzylamino) 7h Pyrrolo[2, 3 D]pyrimidine, Bevacizumab, Cetuximab, Cisplatin, Cyclophosphamide, Doxorubicin, Epidermal Growth Factor Receptor Kinase Inhibitor, Erlotinib, Fluorodeoxyglucose F 18, Fluorouracil, Gefitinib, Histone Deacetylase Inhibitor, Irinotecan, Prednisone, Rituximab, Tracer, Trastuzumab, Tumor Marker, Vincristine, Angiogenesis, Apoptosis, Breast Cancer, Cancer Cell, Cancer Diagnosis, Cancer Invasion, Cancer Research, Cell Proliferation, Colon Carcinoma, Computer Assisted Tomography, Drug Mechanism, Fibrosarcoma, Follicular Lymphoma, Gene Targeting, Glioblastoma, Human, Lung Non Small Cell Cancer, Metastasis, Nonhuman, Positron Emission Tomography, Priority Journal, Protein Expression, Review, Squamous Cell Carcinoma, Treatment Response, Animals, Neoplasms, Positron-Emission Tomography, X-Ray Computed, Neoplasms Diagnosis Radiography Radionuclide Imaging, Positron-Emission Tomography Methods, X-Ray Computed Methods, 6 (4 Hydroxyphenyl) 4 (alpha Methylbenzylamino) 7h Pyrrolo [2, 3 D] Pyrimidine, Neoplasms Diagnosis Diagnostic Imaging,
Affiliations:
*** IBB - CNR ***
Department of Biomorphological and Functional Sciences, University of Naples 'Federico II', Edificio 10, Via S. Pansini, 5, Naples 80131, Italy
Institute of Biostructures and Bioimages, National Research Council, Naples, Italy
References:
Hanahan, D., Weinberg, R.A., The hallmarks of cancer (2000) Cell, 100, pp. 57-7
Kang, J.H., Chung, J.K., Molecular-genetic imaging based on reporter gene expression (2008) J Nucl Med, 49 (SUPPL. 2), pp. 164S-179S
Bading, J.R., Shields, A.F., Imaging of cell proliferation: Status and prospects (2008) J Nucl Med, 49 (SUPPL. 2), pp. 64S-80S
Salskov, A., Tammisetti, V.S., Grierson, J., Vesselle, H., FLT: Measuring tumor cell proliferation in vivo with positron emission tomography and 3′-deoxy-3′-(18F)fluorothymidine (2007) Semin Nucl Med, 37, pp. 429-439
Buck, A.K., Schirrmeister, H., Hetzel, M., Von Der Heide, M., Halter, G., Glatting, G., Mattfeldt, T., Neumaier, B., 3-deoxy-3-((18)F)fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules (2002) Cancer Res, 62, pp. 3331-3334
Vesselle, H., Grierson, J., Muzi, M., Pugsley, J.M., Schmidt, R.A., Rabinowitz, P., Peterson, L.M., Wood, D.E., In vivo validation of 3′deoxy-3′-((18)F)fluorothymidine (((18)F)FLT) as a proliferation imaging tracer in humans: Correlation of ((18)F)FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors (2002) Clin Cancer Res, 8, pp. 3315-3323
Dittmann, H., Dohmen, B.M., Paulsen, F., Eichhorn, K., Eschmann, S.M., Horger, M., Wehrmann, M., Bares, R., (18F)FLT PET for diagnosis and staging of thoracic tumours (2003) Eur J Nucl Med Mol Imag, 30, pp. 1407-1412
Buck, A.K., Halter, G., Schirrmeister, H., Kotzerke, J., Wurziger, I., Glatting, G., Mattfeldt, T., Hetzel, M., Imaging proliferation in lung tumors with PET:18F-FLT versus 18F-FDG (2003) J Nucl Med, 44, pp. 1426-1431
Muzi, M., Vesselle, H., Grierson, J.R., Mankoff, D.A., Schmidt, R.A., Peterson, L., Wells, J.M., Krohn, K.A., Kinetic analysis of 3′-deoxy- 3′-fluorothymidine PET studies: Validation studies in patients with lung cancer (2005) J Nucl Med, 46, pp. 274-282
Buck, A.K., Hetzel, M., Schirrmeister, H., Halter, G., Moller, P., Kratochwil, C., Wahl, A., Reske, S.N., Clinical relevance of imaging proliferative activity in lung nodules (2005) Eur J Nucl Med Mol Imag, 32, pp. 525-533
Yap, C.S., Czernin, J., Fishbein, M.C., Cameron, R.B., Schiepers, C., Phelps, M.E., Weber, W.A., Evaluation of thoracic tumors with18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography (2006) Chest, 129, pp. 393-401
Van Westreenen, H.L., Cobben, D.C., Jager, P.L., Van Dullemen, H.M., Wesseling, J., Elsinga, P.H., Plukker, J.T., Comparison of18F-FLT PET and18F-FDG PET in esophageal cancer (2005) J Nucl Med, 46, pp. 400-404
Francis, D.L., Visvikis, D., Costa, D.C., Arulampalam, T.H., Townsend, C., Luthra, S.K., Taylor, I., Ell, P.J., Potential impact of (18F)3′-deoxy- 3′- fluorothymidine versus (18F)fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer (2003) Eur J Nucl Med Mol Imag, 30, pp. 988-994
Visvikis, D., Francis, D., Mulligan, R., Costa, D.C., Croasdale, I., Luthra, S.K., Taylor, I., Ell, P.J., Comparison of methodologies for the in vivo assessment of18FLT utilisation in colorectal cancer (2004) Eur J Nucl Med Mol Imag, 31, pp. 169-178
Wagner, M., Seitz, U., Buck, A., Neumaier, B., Schultheiss, S., Bangerter, M., Bommer, M., Reske, S.N., 3′-(18F)fluoro-3′-deoxythymidine (( 18F)-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease (2003) Cancer Res, 63, pp. 2681-2687
Jacobs, A.H., Thomas, A., Kracht, L.W., Li, H., Dittmar, C., Garlip, G., Galldiks, N., Heiss, W.D., 18F-fluoro-L-thymidine and11C-methylmethionine as markers of increased transport and proliferation in brain tumors (2005) J Nucl Med, 46, pp. 1948-1958
Choi, S.J., Kim, J.S., Kim, J.H., Oh, S.J., Lee, J.G., Kim, C.J., Ra, Y.S., Moon, D.H., (18F)3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors (2005) Eur J Nucl Med Mol Imag, 32, pp. 653-659
Chen, W., Cloughesy, T., Kamdar, N., Satyamurthy, N., Bergsneider, M., Liau, L., Mischel, P., Silverman, D.H., Imaging proliferation in brain tumors with18F-FLT PET: Comparison with18F-FDG (2005) J Nucl Med, 46, pp. 945-952
Kenny, L.M., Vigushin, D.M., Al-Nahhas, A., Osman, S., Luthra, S.K., Shousha, S., Coombes, R.C., Aboagye, E.O., Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by (18F)fluorothymidine-positron emission tomography imaging: Evaluation of analytical methods (2005) Cancer Res, 65, pp. 10104-11012
Leyton, J., Latigo, J.R., Perumal, M., Dhaliwal, H., He, Q., Aboagye, E.O., Early detection of tumor response to chemotherapy by 3′-deoxy- 3′-(18F)fluorothymidine positron emission tomography: The effect of cisplatin on a fibrosarcoma tumor model in vivo (2005) Cancer Res, 65, pp. 4202-4210
Barthel, H., Cleij, M.C., Collingridge, D.R., Hutchinson, O.C., Osman, S., He, Q., Luthra, S.K., Aboagye, E.O., 3′-deoxy- 3′-(18F)fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography (2003) Cancer Res, 63, pp. 3791-3798
Perumal, M., Pillai, R.G., Barthel, H., Leyton, J., Latigo, J.R., Forster, M., Mitchell, F., Aboagye, E.O., Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography (2006) Cancer Res, 66, pp. 8558-8564
Buck, A.K., Kratochwil, C., Glatting, G., Juweid, M., Bommer, M., Tepsic, D., Vogg, A.T.J., Reske, S.N., Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT (2007) European Journal of Nuclear Medicine and Molecular Imaging, 34 (11), pp. 1775-1782. , DOI 10.1007/s00259-007-0452-z
Graf, N., Herrmann, K., Den Hollander, J., Fend, F., Schuster, T., Wester, H.J., Senekowitsch-Schmidtke, R., Buck, A.K., Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment (2008) Mol Imag Biol, 10, pp. 349-355
Leyton, J., Alao, J.P., Da Costa, M., Stavropoulou, A.V., Latigo, J.R., Perumal, M., Pillai, R., Aboagye, E.O., In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3′-deoxy-3′-(18F)fluorothymidine positron emission tomography (2006) Cancer Res, 66, pp. 7621-7629
Waldherr, C., Mellinghoff, I.K., Tran, C., Halpern, B.S., Rozengurt, N., Safaei, A., Weber, W.A., Czernin, J., Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′-18F-fluorothymidine PET (2005) J Nucl Med, 46, pp. 114-120
Ullrich, R.T., Zander, T., Neumaier, B., Koker, M., Shimamura, T., Waerzeggers, Y., Borgman, C.L., Winkeler, A., Early detection of erlotinib treatment response in NSCLC by 3′-deoxy-3′-(F)-fluoro-L-thymidine ((F)FLT) positron emission tomography (PET) (2008) PLoS ONE, 3, pp. e3908
Leyton, J., Smith, G., Lees, M., Perumal, M., Nguyen, Q.D., Aigbirhio, F.I., Golovko, O., Aboagye, E.O., Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901 (2008) Mol Cancer Ther, 7, pp. 3112-3121
Chen, W., Delaloye, S., Silverman, D.H., Geist, C., Czernin, J., Sayre, J., Satyamurthy, N., Cloughesy, T., Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with (18F) fluorothymidine positron emission tomography: A pilot study (2007) J Clin Oncol, 25, pp. 4714-4721
Herrmann, K., Wieder, H.A., Buck, A.K., Schoffel, M., Krause, B.J., Fend, F., Schuster, T., Dechow, T., Early response assessment using 3′-deoxy-3′-( 18F)fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma (2007) Clin Cancer Res, 13, pp. 3552-3558
Kenny, L., Coombes, R.C., Vigushin, D.M., Al-Nahhas, A., Shousha, S., Aboagye, E.O., Imaging early changes in proliferation at 1 week post chemotherapy: A pilot study in breast cancer patients with 3′-deoxy-3′-( 18F)fluorothymidine positron emission tomography (2007) Eur J Nucl Med Mol Imag, 34, pp. 1339-1347
Wieder, H.A., Geinitz, H., Rosenberg, R., Lordick, F., Becker, K., Stahl, A., Rummeny, E., Stollfuss, J., PET imaging with (18F)3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer (2007) Eur J Nucl Med Mol Imag, 34, pp. 878-883
Herbst, R.S., Fukuoka, M., Baselga, J., Gefitinib - A novel targeted approach to treating cancer (2004) Nat Rev Cancer, 4, pp. 956-965
Cai, W., Niu, G., Chen, X., Multimodality imaging of the HER-kinase axis in cancer (2008) Eur J Nucl Med Mol Imag, 35, pp. 186-208
Perk, L.R., Visser, G.W., Vosjan, M.J., Stigter-van Walsum, M., Tijink, B.M., Leemans, C.R., Van Dongen, G.A., (89)Zr as a PET surrogate radio-isotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab (2005) J Nucl Med, 46, pp. 1898-1906
Cai, W., Chen, K., He, L., Cao, Q., Koong, A., Chen, X., Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody (2007) Eur J Nucl Med Mol Imag, 34, pp. 850-858
Aerts, H.J., Dubois, L., Perk, L., Vermaelen, P., Van Dongen, G.A., Wouters, B.G., Lambin, P., Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET (2009) J Nucl Med, 50, pp. 123-131
Velikyan, I., Sundberg, A.L., Lindhe, O., Hoglund, A.U., Eriksson, O., Werner, E., Carlsson, J., Tolmachev, V., Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors (2005) J Nucl Med, 46, pp. 1881-1888
Bonasera, T.A., Ortu, G., Rozen, Y., Krais, R., Freedman, N.M., Chisin, R., Gazit, A., Mishani, E., Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase (2001) Nucl Med Biol, 28, pp. 359-374
Ortu, G., Ben-David, I., Rozen, Y., Freedman, N.M., Chisin, R., Levitzki, A., Mishani, E., Labeled EGFr-TK irreversible inhibitor (ML03): In vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug (2002) Int J Cancer, 101, pp. 360-370
Pal, A., Glekas, A., Doubrovin, M., Balatoni, J., Namavari, M., Beresten, T., Maxwell, D., Gelovani, J.G., Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography (2006) Mol Imag Biol, 8, pp. 262-877
Mishani, E., Abourbeh, G., Jacobson, O., Dissoki, S., Ben Daniel, R., Rozen, Y., Shaul, M., Levitzki, A., High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors (2005) J Med Chem, 48, pp. 5337-5348
Abourbeh, G., Dissoki, S., Jacobson, O., Litchi, A., Ben Daniel, R., Laki, D., Levitzki, A., Mishani, E., Evaluation of radiolabeled ML04:A putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors (2007) Nucl Med Biol, 34, pp. 55-70
Wang, J.Q., Gao, M., Miller, K.D., Sledge, G.W., Zheng, Q.H., Synthesis of (11C)Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase (2006) Bioorg Med Chem Lett, 16, pp. 4102-4106
Memon, A.A., Jakobsen, S., Dagnaes-Hansen, F., Sorensen, B.S., Keiding, S., Nexo, E., Positron emission tomography (PET) imaging with (11C)-labeled erlotinib: A micro-PET study on mice with lung tumor xenografts (2009) Cancer Res, 69, pp. 873-878
Seimbille, Y., Phelps, M.E., Czernin, J., Silverman, D.S., Fluorin-18 labeling of 6,7-distributed anilinoquinazoline derivates, for positron emission tomography (PET) imaging of tyrosine kinase receptors: Syntesis of18F-Iressa and related molecular probes (2005) J Label Compd Radiopharm, 48, pp. 829-843
Su, H., Seimbille, Y., Ferl, G.Z., Bodenstein, C., Fueger, B., Kim, K.J., Hsu, Y.T., Weber, W.A., Evaluation of ((18)F)gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors (2008) Eur J Nucl Med Mol Imag, 35, pp. 1089-1099
Liu, N., Li, M., Li, X., Meng, X., Yang, G., Zhao, S., Yang, Y., Yu, J., PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer11C-PD153035 in humans (2009) J Nucl Med, 50, pp. 303-308
Fredriksson, A., Johnstrom, P., Thorell, J.O., Von Heijne, G., Hassan, M., Eksborg, S., Kogner, P., Stone-Elander, S., In vivo evaluation of the biodistribution of11C-labeled PD153035 in rats without and with neuroblastoma implants (1999) Life Sci, 65, pp. 165-174
Sergina, N.V., Moasser, M.M., The HER family and cancer: Emerging molecular mechanisms and therapeutic targets (2007) Trends in Molecular Medicine, 13 (12), pp. 527-534. , DOI 10.1016/j.molmed.2007.10.002, PII S1471491407001864
Di Cosimo, S., Baselga, J., Targeted therapies in breast cancer: Where are we now? (2008) Eur J Cancer, 44, pp. 2781-2790
Nielsen, D.L., Andersson, M., Kamby, C., HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors (2009) Cancer Treat Rev, 35, pp. 121-136
Dean-Colomb, W., Esteva, F.J., Her2-positive breast cancer: Herceptin and beyond (2008) Eur J Cancer, 44, pp. 2806-2812
Robinson, M.K., Doss, M., Shaller, C., Narayanan, D., Marks, J.D., Adler, L.P., De Trotter, G., Adams, G.P., Quantitative immunopositron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody (2005) Cancer Res, 65, pp. 1471-1478
Olafsen, T., Kenanova, V.E., Sundaresan, G., Anderson, A.L., Crow, D., Yazaki, P.J., Li, L., Wu, A.M., Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging (2005) Cancer Res, 65, pp. 5907-5916
Garmestani, K., Milenic, D.E., Plascjak, P.S., Brechbiel, M.W., A new and convenient method for purification of86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111in labeled Herceptin (2002) Nucl Med Biol, 29, pp. 599-606
Smith-Jones, P.M., Solit, D.B., Akhurst, T., Afroze, F., Rosen, N., Larson, S.M., Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors (2004) Nat Biotechnol, 22, pp. 701-706
Tolmachev, V., Imaging of HER-2 overexpression in tumors for guiding therapy (2008) Curr Pharm des, 14, pp. 2999-3019
Orlova, A., Wallberg, H., Stone-Elander, S., Tolmachev, V., On the selection of a tracer for PET imaging of HER2-expressing tumors: Direct comparison of a124I-labeled affibody molecule and trastuzumab in a murine xenograft model (2009) J Nucl Med, 50, pp. 417-425
Cheng, Z., De Jesus, O.P., Namavari, M., De, A., Levi, J., Webster, J.M., Zhang, R., Gambhir, S.S., Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific18F-labeled protein scaffold molecules (2008) J Nucl Med, 49, pp. 804-813
Chen, X., Conti, P.S., Moats, R.A., In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts (2004) Cancer Res, 64, pp. 8009-8014
Sipkins, D.A., Cheresh, D.A., Kazemi, M.R., Nevin, L.M., Bednarski, M.D., Li, K.C., Detection of tumor angiogenesis in vivo by alphaVbeta3- targeted magnetic resonance imaging (1998) Nat Med, 4, pp. 623-626
Zhang, C., Jugold, M., Woenne, E.C., Lammers, T., Morgenstern, B., Mueller, M.M., Zentgraf, H., Kiessling, F., Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner (2007) Cancer Res, 67, pp. 1555-1562
Ellegala, D.B., Leong-Poi, H., Carpenter, J.E., Klibanov, A.L., Kaul, S., Shaffrey, M.E., Sklenar, J., Lindner, J.R., Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3 (2003) Circulation, 108, pp. 336-341
Janssen, M.L., Oyen, W.J., Dijkgraaf, I., Massuger, L.F., Frielink, C., Edwards, D.S., Rajopadhye, M., Boerman, O.C., Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model (2002) Cancer Res, 62, pp. 6146-6151
Haubner, R., Wester, H.J., Weber, W.A., Mang, C., Ziegler, S.I., Goodman, S.L., Senekowitsch-Schmidtke, R., Schwaiger, M., Non-invasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography (2001) Cancer Res, 61, pp. 1781-1785
Chen, X., Hou, Y., Tohme, M., Park, R., Khankaldyyan, V., Gonzales-Gomez, I., Bading, J.R., Conti, P.S., Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression (2004) J Nucl Med, 45, pp. 1776-1783
Cai, W., Wu, Y., Chen, K., Cao, Q., Tice, D.A., Chen, X., In vitro and in vivo characterization of64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3 (2006) Cancer Res, 66, pp. 9673-9681
Haubner, R., Weber, W.A., Beer, A.J., Vabuliene, E., Reim, D., Sarbia, M., Becker, K.F., Schwaiger, M., Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and (18F)Galacto-RGD (2005) PLoS Med, 2, p. 70
Beer, A.J., Haubner, R., Sarbia, M., Goebel, M., Luderschmidt, S., Grosu, A.L., Schnell, O., Schwaiger, M., Positron emission tomography using (18F)Galacto- RGD identifies the level of integrin alpha(v)beta3 expression in man (2006) Clin Cancer Res, 12, pp. 3942-3949
Beer, A.J., Grosu, A.L., Carlsen, J., Kolk, A., Sarbia, M., Stangier, I., Watzlowik, P., Schwaiger, M., (18F)galacto- RGD positron emission tomography for imaging of alphav-beta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck (2007) Clin Cancer Res, 13, pp. 6610-6616
Beer, A.J., Niemeyer, M., Carlsen, J., Sarbia, M., Nahrig, J., Watzlowik, P., Wester, H.J., Schwaiger, M., Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by18F-Galacto-RGD PET (2008) J Nucl Med, 49, pp. 255-259
Zannetti, A., Del Vecchio, S., Iommelli, F., Del Gatto, A., De Luca, S., Zaccaro, L., Papaccioli, A., Salvatore, M., Imaging of alphavbeta3 expression by a bifunctional chimeric RGD peptide not cross-reacting with alphavbeta5 (2009) Clin Cancer Res, 15, pp. 5224-5233
Wu, Y., Zhang, X., Xiong, Z., Cheng, Z., Fisher, D.R., Liu, S., Gambhir, S.S., Chen, X., MicroPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide (2005) J Nucl Med, 46, pp. 1707-1718
Kenny, L.M., Coombes, R.C., Oulie, I., Contractor, K.B., Miller, M., Spinks, T.J., McParland, B., Aboagye, E.O., Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand18F-AH111585 in breast cancer patients (2008) J Nucl Med, 49, pp. 879-886
Chen, X., Park, R., Hou, Y., Khankaldyyan, V., Gonzales-Gomez, I., Tohme, M., Bading, J.R., Conti, P.S., MicroPET imaging of brain tumor angiogenesis with18F-labeled PEGylated RGD peptide (2004) Eur J Nucl Med Mol Imag, 31, pp. 1081-1089
Waxman, D.J., Schwartz, P.S., Harnessing Apoptosis for Improved Anticancer Gene Therapy (2003) Cancer Research, 63 (24), pp. 8563-8572
Blankenberg, F.G., In vivo imaging of apoptosis (2008) Cancer Biol Ther, 7, pp. 1525-1532
Yagle, K.J., Eary, J.F., Tait, J.F., Grierson, J.R., Link, J.M., Lewellen, B., Gibson, D.F., Krohn, K.A., Evaluation of18F-annexin V as a PET imaging agent in an animal model of apoptosis (2005) J Nucl Med, 46, pp. 658-866
Dekker, B., Keen, H., Lyons, S., Disley, L., Hastings, D., Reader, A., Ottewell, P., Zweit, J., MBP-annexin V radiolabeled directly with iodine-124 can be used to image apoptosis in vivo using PET (2005) Nucl Med Biol, 32, pp. 241-252
Keen, H.G., Dekker, B.A., Disley, L., Hastings, D., Lyons, S., Reader, A.J., Ottewell, P., Zweit, J., Imaging apoptosis in vivo using124I-annexin V and PET (2005) Nucl Med Biol, 32, pp. 395-402
Cauchon, N., Langlois, R., Rousseau, J.A., Tessier, G., Cadorette, J., Lecomte, R., Hunting, D.J., Van Lier, J.E., PET imaging of apoptosis with (64)Cu-labeled streptavidin following pretargeting of phosphatidylserine with biotinylated annexin-V (2007) Eur J Nucl Med Mol Imag, 34, pp. 247-258
Gottlieb, R.A., Kitsis, R.N., Seeing death in the living (2001) Nat Med, 7, pp. 1277-1278
Brouckaert, G., Kalai, M., Krysko, D.V., Saelens, X., Vercammen, D., Ndlovu, M., Haegeman, G., Vandenabeele, P., Phagocytosis of necrotic cells by macrophages is phosphatidylserine dependent and does not induce inflammatory cytokine production (2004) Mol Biol Cell, 15, pp. 1089-1100
Lee, D., Long, S.A., Adams, J.L., Chan, G., Vaidya, K.S., Francis, T.A., Kikly, K., Nuttall, M.E., Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality (2000) J Biol Chem, 275, pp. 16007-16014
Nguyen, Q.D., Smith, G., Glaser, M., Perumal, M., Arstad, E., Aboagye, E.O., Positron Emission tomography imaging of drug-induced apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide (2009) Proc Natl Acad Sci USA, 106, pp. 16375-16380
Zhou, D., Chu, W., Chen, D.L., Wang, Q., Reichert, D.E., Rothfuss, J., D'Avignon, A., Mach, R.H., (18F)- and (11C)-labeled N-benzyl-isatin sulfonamide analogues as PET tracers for apoptosis: Synthesis, radiolabeling mechanism, and in vivo imaging study of apoptosis in Fas-treated mice using (11C)WC-98 (2009) Org Biomol Chem, 7, pp. 1337-1348
Madar, I., Ravert, H., Nelkin, B., Abro, M., Pomper, M., Dannals, R., Frost, J.J., Characterization of membrane potential-dependent uptake of the novel PET tracer18F-fluorobenzyl triphenylphosphonium cation (2007) Eur J Nucl Med Mol Imag, 34, pp. 2057-2065
Aloya, R., Shirvan, A., Grimberg, H., Reshef, A., Levin, G., Kidron, D., Cohen, A., Ziv, I., Molecular imaging of cell death in vivo by a novel small molecule probe (2006) Apoptosis, 11, pp. 2089-2101
Zeng, W., Yao, M.L., Townsend, D., Kabalka, G., Wall, J., Le Puil, M., Biggerstaff, J., Miao, W., Synthesis, biological evaluation and radiochemical labeling of a dansylhydrazone derivative as a potential imaging agent for apoptosis (2008) Bioorg Med Chem Lett, 18, pp. 3573-3577
Reshef, A., Shirvan, A., Waterhouse, R.N., Grimberg, H., Levin, G., Cohen, A., Ulysse, L.G., Ziv, I., Molecular imaging of neurovascular cell death in experimental cerebral stroke by PET (2008) J Nucl Med, 49, pp. 1520-1528
Shirvan, A., Reshef, A., Allen, A., Fenig, E., Steinmetz, A., Groshar, D., Mishani, E., Ziv, I., Apoptosis imaging with PET-18F-ML-10 for early assessment of response of brain metastases to radiotherapy (2009) J Nucl Med, 50, p. 43
Scherer, R.L., McIntyre, J.O., Matrisian, L.M., Imaging matrix metalloproteinases in cancer (2008) Cancer Metastasis Rev, 27, pp. 679-690
Furumoto, S., Takashima, K., Kubota, K., Ido, T., Iwata, R., Fukuda, H., Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor (2003) Nucl Med Biol, 30, pp. 119-125
Zheng, Q.H., Fei, X., Liu, X., Wang, J.Q., Sun, B., Mock, H., Lee, B.H., Hutchins, G.D., Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers (11C)methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents (2002) Nucl Med Biol, 29, pp. 761-770
Wagner, S., Breyholz, H.J., Holtke, C., Faust, A., Schober, O., Schafers, M., Kopka, K., A new 18F-labelled derivative of the MMP inhibitor CGS 27023A for PET: Radiosynthesis and initial small-animal PET studies (2009) Appl Radiat Isot, 67, pp. 606-610
D'Alessio, S., Blasi, F., The urokinase receptor as an entertainer of signal transduction (2009) Front Biosci, 14, pp. 4575-4587
Dass, K., Ahmad, A., Azmi, A.S., Sarkar, S.H., Sarkar, F.H., Evolving role of uPA/uPAR system in human cancers (2008) Cancer Treat Rev, 34, pp. 122-136
Del Vecchio, S., Stoppelli, M.P., Carriero, M.V., Fonti, R., Massa, O., Li, P.Y., Botti, G., Esposito, G., Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: Comparison with urokinase levels (1993) Cancer Res, 53, pp. 3198-3206
Mohanam, S., Chintala, S.K., Go, Y., Bhattacharya, A., Venkaiah, B., Boyd, D., Gokaslan, Z.L., Rao, J.S., In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor (1997) Oncogene, 14, pp. 1351-1359
Rabbani, S.A., Gladu, J., Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo (2002) Cancer Research, 62 (8), pp. 2390-2397
Subramanian, R., Gondi, C.S., Lakka, S.S., Jutla, A., Rao, J.S., SiRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells (2006) Int J Oncol, 28, pp. 831-839
Li, Z.B., Niu, G., Wang, H., He, L., Yang, L., Ploug, M., Chen, X., Imaging of urokinase-type plasminogen activator receptor expression using a64Cu-labeled linear peptide antagonist by microPET (2008) Clin Cancer Res, 14, pp. 4758-4766
Albelda, S.M., Mette, S.A., Elder, D.E., Stewart, R., Damjanovich, L., Herlyn, M., Buck, C.A., Integrin distribution in malignant melanoma: Association of the beta 3 subunit with tumor progression (1990) Cancer Res, 50, pp. 6757-6764
Schnell, O., Krebs, B., Wagner, E., Romagna, A., Beer, A.J., Grau, S.J., Thon, N., Goldbrunner, R.H., Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature (2008) Brain Pathol, 18, pp. 378-386
Liapis, H., Adler, L.M., Wick, M.R., Rader, J.S., Expression of alpha(v)- beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas (1997) Hum Pathol, 28, pp. 443-449
Gasparini, G., Brooks, P.C., Biganzoli, E., Vermeulen, P.B., Bonoldi, E., Dirix, L.Y., Ranieri, G., Cheresh, D.A., Vascular integrin alpha(v)beta3: A new prognostic indicator in breast cancer (1998) Clin Cancer Res, 4, pp. 2625-2634
Felding-Habermann, B., O'Toole, T.E., Smith, J.W., Fransvea, E., Ruggeri, Z.M., Ginsberg, M.H., Hughes, P.E., Mueller, B.M., Integrin activation controls metastasis in human breast cancer (2001) Proc Natl Acad Sci USA, 98, pp. 1853-1858
Rolli, M., Fransvea, E., Pilch, J., Saven, A., Felding-Habermann, B., Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells (2003) Proceedings of the National Academy of Sciences of the United States of America, 100 (16), pp. 9482-9487. , DOI 10.1073/pnas.1633689100
Carriero, M.V., Del Vecchio, S., Capozzoli, M., Franco, P., Fontana, L., Zannetti, A., Botti, G., Stoppelli, M.P., Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer (1999) Cancer Res, 59, pp. 5307-5314
Beer, A.J., Schwaiger, M., Imaging of integrin alphavbeta3 expression (2008) Cancer Metastasis Rev, 27, pp. 631-644
Koizumi, K., Hojo, S., Akashi, T., Yasumoto, K., Saiki, I., Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response (2007) Cancer Sci, 98, pp. 1652-1658
Jacobson, O., Weiss, I.D., Szajek, L., Farber, J.M., Kiesewetter, D.O., 64Cu-AMD3100 - A novel imaging agent for targeting chemokine receptor CXCR4 (2009) Bioorg Med Chem, 17, pp. 1486-1493
Fletcher, J.W., Djulbegovic, B., Soares, H.P., Siegel, B.A., Lowe, V.J., Lyman, G.H., Coleman, R.E., Shields, A.F., Recommendations on the use of18F-FDG PET in oncology (2008) J Nucl Med, 49, pp. 480-508
Mawlawi, O., Townsend, D.W., Multimodality imaging: An update on PET/CT technology (2009) Eur J Nucl Med Mol Imag, 36 (SUPPL. 1), pp. S15-29
Plathow, C., Weber, W.A., Tumor cell metabolism imaging (2008) J Nucl Med, 49 (SUPPL. 2), pp. 43S-63S
Kim, J.W., Dang, C.V., Cancer's molecular sweet tooth and the Warburg effect (2006) Cancer Res, 66, pp. 8927-8930
Gillies, R.J., Robey, I., Gatenby, R.A., Causes and consequences of increased glucose metabolism of cancers (2008) J Nucl Med, 49 (SUPPL. 2), pp. 24S-42S
Townsend, D.W., Dual-modality imaging: Combining anatomy and function (2008) J Nucl Med, 49, pp. 938-955
Ben-Haim, S., Ell, P., 18F-FDG PET and PET/CT in the evaluation of cancer treatment response (2009) J Nucl Med, 50, pp. 88-99
Hutchings, M., Barrington, S.F., PET/CT for therapy response assessment in lymphoma (2009) J Nucl Med, 50 (SUPPL.), pp. 21S-30S
Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Diehl, V., Revised response criteria for malignant lymphoma (2007) J Clin Oncol, 25, pp. 579-586
Wahl, R.L., Jacene, H., Kasamon, Y., Lodge, M.A., From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors (2009) J Nucl Med, 50 (SUPPL. 1), pp. 122S-a50S
Vriens, D., De Geus-Oei, L.F., Van Der Graaf, W.T.A., Oyen, W.J.G., Tailoring therapy in colorectal cancer by PET-CT (2009) Q J Nucl Med Mol Imag, 53, pp. 224-244
Chuang, H.H., Macapinlac, H.A., The evolving role of PET-CT in the management of esophageal cancer (2009) Q J Nucl Med Mol Imag, 53, pp. 201-209
Hichs, R., Role of18F-FDG PET in assessment of response in non-small cell lung cancer (2009) J Nucl Med, 50 (SUPPL.), pp. 31S-42S
Pons, F., Duch, J., Fuster, D., Breast cancer therapy: The role of PET-CT in decision making (2009) Q J Nucl Med Mol Imag, 53, pp. 210-223
Lordick, F., Ott, K., Krause, B.J., Weber, W.A., Becker, K., Stein, H.J., Lorenzen, S., Siewert, J.R., PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial (2007) Lancet Oncol, 8, pp. 797-805
Delso, G., Ziegler, S., PET/MRI system design (2009) Eur J Nucl Med Mol Imag, 36 (SUPPL. 1), pp. S86-92
Pichler, B.J., Wehrl, H.F., Judenhofer, M.S., Latest advances in molecular imaging instrumentation (2008) J Nucl Med, 49 (SUPPL. 2), pp. 5S-23S
Kang, J. H., Chung, J. K., Molecular-genetic imaging based on reporter gene expression (2008) J Nucl Med, 49 (SUPPL. 2), pp. 164S-179S
Bading, J. R., Shields, A. F., Imaging of cell proliferation: Status and prospects (2008) J Nucl Med, 49 (SUPPL. 2), pp. 64S-80S
Buck, A. K., Schirrmeister, H., Hetzel, M., Von Der Heide, M., Halter, G., Glatting, G., Mattfeldt, T., Neumaier, B., 3-deoxy-3- ((18) F) fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules (2002) Cancer Res, 62, pp. 3331-3334
Buck, A. K., Halter, G., Schirrmeister, H., Kotzerke, J., Wurziger, I., Glatting, G., Mattfeldt, T., Hetzel, M., Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG (2003) J Nucl Med, 44, pp. 1426-1431
Buck, A. K., Hetzel, M., Schirrmeister, H., Halter, G., Moller, P., Kratochwil, C., Wahl, A., Reske, S. N., Clinical relevance of imaging proliferative activity in lung nodules (2005) Eur J Nucl Med Mol Imag, 32, pp. 525-533
Yap, C. S., Czernin, J., Fishbein, M. C., Cameron, R. B., Schiepers, C., Phelps, M. E., Weber, W. A., Evaluation of thoracic tumors with18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography (2006) Chest, 129, pp. 393-401
Van Westreenen, H. L., Cobben, D. C., Jager, P. L., Van Dullemen, H. M., Wesseling, J., Elsinga, P. H., Plukker, J. T., Comparison of18F-FLT PET and18F-FDG PET in esophageal cancer (2005) J Nucl Med, 46, pp. 400-404
Francis, D. L., Visvikis, D., Costa, D. C., Arulampalam, T. H., Townsend, C., Luthra, S. K., Taylor, I., Ell, P. J., Potential impact of (18F) 3 -deoxy- 3 - fluorothymidine versus (18F) fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer (2003) Eur J Nucl Med Mol Imag, 30, pp. 988-994
Jacobs, A. H., Thomas, A., Kracht, L. W., Li, H., Dittmar, C., Garlip, G., Galldiks, N., Heiss, W. D., 18F-fluoro-L-thymidine and11C-methylmethionine as markers of increased transport and proliferation in brain tumors (2005) J Nucl Med, 46, pp. 1948-1958
Choi, S. J., Kim, J. S., Kim, J. H., Oh, S. J., Lee, J. G., Kim, C. J., Ra, Y. S., Moon, D. H., (18F) 3 -deoxy-3 -fluorothymidine PET for the diagnosis and grading of brain tumors (2005) Eur J Nucl Med Mol Imag, 32, pp. 653-659
Kenny, L. M., Vigushin, D. M., Al-Nahhas, A., Osman, S., Luthra, S. K., Shousha, S., Coombes, R. C., Aboagye, E. O., Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by (18F) fluorothymidine-positron emission tomography imaging: Evaluation of analytical methods (2005) Cancer Res, 65, pp. 10104-11012
Buck, A. K., Kratochwil, C., Glatting, G., Juweid, M., Bommer, M., Tepsic, D., Vogg, A. T. J., Reske, S. N., Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F] FLT (2007) European Journal of Nuclear Medicine and Molecular Imaging, 34 (11), pp. 1775-1782. , DOI 10. 1007/s00259-007-0452-z
Ullrich, R. T., Zander, T., Neumaier, B., Koker, M., Shimamura, T., Waerzeggers, Y., Borgman, C. L., Winkeler, A., Early detection of erlotinib treatment response in NSCLC by 3 -deoxy-3 - (F) -fluoro-L-thymidine ((F) FLT) positron emission tomography (PET) (2008) PLoS ONE, 3, pp. e3908
Wieder, H. A., Geinitz, H., Rosenberg, R., Lordick, F., Becker, K., Stahl, A., Rummeny, E., Stollfuss, J., PET imaging with (18F) 3 -deoxy-3 -fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer (2007) Eur J Nucl Med Mol Imag, 34, pp. 878-883
Herbst, R. S., Fukuoka, M., Baselga, J., Gefitinib - A novel targeted approach to treating cancer (2004) Nat Rev Cancer, 4, pp. 956-965
Perk, L. R., Visser, G. W., Vosjan, M. J., Stigter-van Walsum, M., Tijink, B. M., Leemans, C. R., Van Dongen, G. A., (89) Zr as a PET surrogate radio-isotope for scouting biodistribution of the therapeutic radiometals (90) Y and (177) Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab (2005) J Nucl Med, 46, pp. 1898-1906
Aerts, H. J., Dubois, L., Perk, L., Vermaelen, P., Van Dongen, G. A., Wouters, B. G., Lambin, P., Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET (2009) J Nucl Med, 50, pp. 123-131
Bonasera, T. A., Ortu, G., Rozen, Y., Krais, R., Freedman, N. M., Chisin, R., Gazit, A., Mishani, E., Potential (18) F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase (2001) Nucl Med Biol, 28, pp. 359-374
Wang, J. Q., Gao, M., Miller, K. D., Sledge, G. W., Zheng, Q. H., Synthesis of (11C) Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase (2006) Bioorg Med Chem Lett, 16, pp. 4102-4106
Memon, A. A., Jakobsen, S., Dagnaes-Hansen, F., Sorensen, B. S., Keiding, S., Nexo, E., Positron emission tomography (PET) imaging with (11C) -labeled erlotinib: A micro-PET study on mice with lung tumor xenografts (2009) Cancer Res, 69, pp. 873-878
Sergina, N. V., Moasser, M. M., The HER family and cancer: Emerging molecular mechanisms and therapeutic targets (2007) Trends in Molecular Medicine, 13 (12), pp. 527-534. , DOI 10. 1016/j. molmed. 2007. 10. 002, PII S1471491407001864
Nielsen, D. L., Andersson, M., Kamby, C., HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors (2009) Cancer Treat Rev, 35, pp. 121-136
Robinson, M. K., Doss, M., Shaller, C., Narayanan, D., Marks, J. D., Adler, L. P., De Trotter, G., Adams, G. P., Quantitative immunopositron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody (2005) Cancer Res, 65, pp. 1471-1478
Smith-Jones, P. M., Solit, D. B., Akhurst, T., Afroze, F., Rosen, N., Larson, S. M., Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors (2004) Nat Biotechnol, 22, pp. 701-706
Sipkins, D. A., Cheresh, D. A., Kazemi, M. R., Nevin, L. M., Bednarski, M. D., Li, K. C., Detection of tumor angiogenesis in vivo by alphaVbeta3- targeted magnetic resonance imaging (1998) Nat Med, 4, pp. 623-626
Ellegala, D. B., Leong-Poi, H., Carpenter, J. E., Klibanov, A. L., Kaul, S., Shaffrey, M. E., Sklenar, J., Lindner, J. R., Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha (v) beta3 (2003) Circulation, 108, pp. 336-341
Janssen, M. L., Oyen, W. J., Dijkgraaf, I., Massuger, L. F., Frielink, C., Edwards, D. S., Rajopadhye, M., Boerman, O. C., Tumor targeting with radiolabeled alpha (v) beta (3) integrin binding peptides in a nude mouse model (2002) Cancer Res, 62, pp. 6146-6151
Beer, A. J., Haubner, R., Sarbia, M., Goebel, M., Luderschmidt, S., Grosu, A. L., Schnell, O., Schwaiger, M., Positron emission tomography using (18F) Galacto- RGD identifies the level of integrin alpha (v) beta3 expression in man (2006) Clin Cancer Res, 12, pp. 3942-3949
Beer, A. J., Grosu, A. L., Carlsen, J., Kolk, A., Sarbia, M., Stangier, I., Watzlowik, P., Schwaiger, M., (18F) galacto- RGD positron emission tomography for imaging of alphav-beta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck (2007) Clin Cancer Res, 13, pp. 6610-6616
Beer, A. J., Niemeyer, M., Carlsen, J., Sarbia, M., Nahrig, J., Watzlowik, P., Wester, H. J., Schwaiger, M., Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by18F-Galacto-RGD PET (2008) J Nucl Med, 49, pp. 255-259
Kenny, L. M., Coombes, R. C., Oulie, I., Contractor, K. B., Miller, M., Spinks, T. J., McParland, B., Aboagye, E. O., Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand18F-AH111585 in breast cancer patients (2008) J Nucl Med, 49, pp. 879-886
Waxman, D. J., Schwartz, P. S., Harnessing Apoptosis for Improved Anticancer Gene Therapy (2003) Cancer Research, 63 (24), pp. 8563-8572
Blankenberg, F. G., In vivo imaging of apoptosis (2008) Cancer Biol Ther, 7, pp. 1525-1532
Yagle, K. J., Eary, J. F., Tait, J. F., Grierson, J. R., Link, J. M., Lewellen, B., Gibson, D. F., Krohn, K. A., Evaluation of18F-annexin V as a PET imaging agent in an animal model of apoptosis (2005) J Nucl Med, 46, pp. 658-866
Keen, H. G., Dekker, B. A., Disley, L., Hastings, D., Lyons, S., Reader, A. J., Ottewell, P., Zweit, J., Imaging apoptosis in vivo using124I-annexin V and PET (2005) Nucl Med Biol, 32, pp. 395-402
Gottlieb, R. A., Kitsis, R. N., Seeing death in the living (2001) Nat Med, 7, pp. 1277-1278
Lee, D., Long, S. A., Adams, J. L., Chan, G., Vaidya, K. S., Francis, T. A., Kikly, K., Nuttall, M. E., Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality (2000) J Biol Chem, 275, pp. 16007-16014
Nguyen, Q. D., Smith, G., Glaser, M., Perumal, M., Arstad, E., Aboagye, E. O., Positron Emission tomography imaging of drug-induced apoptosis with a caspase-3/7 specific [18F] -labeled isatin sulfonamide (2009) Proc Natl Acad Sci USA, 106, pp. 16375-16380
Zeng, W., Yao, M. L., Townsend, D., Kabalka, G., Wall, J., Le Puil, M., Biggerstaff, J., Miao, W., Synthesis, biological evaluation and radiochemical labeling of a dansylhydrazone derivative as a potential imaging agent for apoptosis (2008) Bioorg Med Chem Lett, 18, pp. 3573-3577
Scherer, R. L., McIntyre, J. O., Matrisian, L. M., Imaging matrix metalloproteinases in cancer (2008) Cancer Metastasis Rev, 27, pp. 679-690
Zheng, Q. H., Fei, X., Liu, X., Wang, J. Q., Sun, B., Mock, H., Lee, B. H., Hutchins, G. D., Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers (11C) methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents (2002) Nucl Med Biol, 29, pp. 761-770
Rabbani, S. A., Gladu, J., Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo (2002) Cancer Research, 62 (8), pp. 2390-2397
Li, Z. B., Niu, G., Wang, H., He, L., Yang, L., Ploug, M., Chen, X., Imaging of urokinase-type plasminogen activator receptor expression using a64Cu-labeled linear peptide antagonist by microPET (2008) Clin Cancer Res, 14, pp. 4758-4766
Albelda, S. M., Mette, S. A., Elder, D. E., Stewart, R., Damjanovich, L., Herlyn, M., Buck, C. A., Integrin distribution in malignant melanoma: Association of the beta 3 subunit with tumor progression (1990) Cancer Res, 50, pp. 6757-6764
Carriero, M. V., Del Vecchio, S., Capozzoli, M., Franco, P., Fontana, L., Zannetti, A., Botti, G., Stoppelli, M. P., Urokinase receptor interacts with alpha (v) beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer (1999) Cancer Res, 59, pp. 5307-5314
Beer, A. J., Schwaiger, M., Imaging of integrin alphavbeta3 expression (2008) Cancer Metastasis Rev, 27, pp. 631-644
Fletcher, J. W., Djulbegovic, B., Soares, H. P., Siegel, B. A., Lowe, V. J., Lyman, G. H., Coleman, R. E., Shields, A. F., Recommendations on the use of18F-FDG PET in oncology (2008) J Nucl Med, 49, pp. 480-508
Kim, J. W., Dang, C. V., Cancer's molecular sweet tooth and the Warburg effect (2006) Cancer Res, 66, pp. 8927-8930
Gillies, R. J., Robey, I., Gatenby, R. A., Causes and consequences of increased glucose metabolism of cancers (2008) J Nucl Med, 49 (SUPPL. 2), pp. 24S-42S
Townsend, D. W., Dual-modality imaging: Combining anatomy and function (2008) J Nucl Med, 49, pp. 938-955
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Diehl, V., Revised response criteria for malignant lymphoma (2007) J Clin Oncol, 25, pp. 579-586
Wahl, R. L., Jacene, H., Kasamon, Y., Lodge, M. A., From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors (2009) J Nucl Med, 50 (SUPPL. 1), pp. 122S-a50S
Chuang, H. H., Macapinlac, H. A., The evolving role of PET-CT in the management of esophageal cancer (2009) Q J Nucl Med Mol Imag, 53, pp. 201-209
Pichler, B. J., Wehrl, H. F., Judenhofer, M. S., Latest advances in molecular imaging instrumentation (2008) J Nucl Med, 49 (SUPPL. 2), pp. 5S-23S
PET/CT in cancer research: From preclinical to clinical applications
The identification of genetic and biochemical mechanisms underlying tumor growth and progression along with the unraveling of human genoma provided a plethora of new targets for cancer detection, treatment and monitoring. Simultaneously, the extraordinary development of a number of imaging technologies, including hybrid systems, allowed the visualization of biochemical, molecular and physiological aberrations linked to underlying mutations in a given tumor. In vivo evaluation of complex biological processes such as proliferation, apoptosis, angiogenesis, metastasis, gene expression, receptor-ligand interactions, transport of substrates and metabolism of nutrients in human cancers is feasible using PET/CT and radiolabeled molecular probes. Some of these compounds are in preclinical phases of evaluation whereas others have been already applied in clinical settings. Here we provide prominent examples on how some biological processes and target expression can be visualized by PET/CT in animal tumor models and cancer patients for the noninvasive detection of well-known markers of tumor aggressiveness, invasiveness and resistance to treatment and for the evaluation of tumor response to therapy. Copyright © 2010 John Wiley & Sons, Ltd.
The identification of genetic and biochemical mechanisms underlying tumor growth and progression along with the unraveling of human genoma provided a plethora of new targets for cancer detection, treatment and monitoring. Simultaneously, the extraordinary development of a number of imaging technologies, including hybrid systems, allowed the visualization of biochemical, molecular and physiological aberrations linked to underlying mutations in a given tumor. In vivo evaluation of complex biological processes such as proliferation, apoptosis, angiogenesis, metastasis, gene expression, receptor-ligand interactions, transport of substrates and metabolism of nutrients in human cancers is feasible using PET/CT and radiolabeled molecular probes. Some of these compounds are in preclinical phases of evaluation whereas others have been already applied in clinical settings. Here we provide prominent examples on how some biological processes and target expression can be visualized by PET/CT in animal tumor models and cancer patients for the noninvasive detection of well-known markers of tumor aggressiveness, invasiveness and resistance to treatment and for the evaluation of tumor response to therapy. Copyright © 2010 John Wiley & Sons, Ltd.
PET/CT in cancer research: From preclinical to clinical applications
| ▼ Complementary use of preclinical imaging in minipig model studies |
| ▼ Phenotyping of murine models by preclinical imaging |
PET/CT in cancer research: From preclinical to clinical applications
Other filter: ([btitle,keywords] "Translational Resear ...
Perri F, Ionna F, Muto P, Marzo MD, Caponigro F, Longo F, Vittoria Scarpati GD, Lorenzo GD, Giuliano M, Solla R
* Genetics and management of locally advanced carcinomas of the head and neck: role of altered fractionation radiotherapy (196 views)
Future Sci Oa (ISSN: 2056-5623linking), 2018 Oct 26; 5(1): FSO347-FSO347.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Zannetti A, Iommelli F, Speranza A, Salvatore M, Del Vecchio S
* 3'-deoxy-3'-18F-fluorothymidine (FLT) PET/CT to guide therapy with epidermal growth factor receptor (EGFR) antagonists and Bcl-xL inhibitors in non-small cell lung cancer (614 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2012 Mar 1; 53(3): 443-450.
Impact Factor: 5.774
View Export to BibTeX Export to EndNote
Zannetti A, Iommelli F, Speranza A, Salvatore M, Del Vecchio S
* 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer (525 views)
J Nucl Med (ISSN: 1535-5667, 0161-5505, 1535-5667electronic), 2012 Mar 1; 53(3): 443-450.
Impact Factor: 5.774
View Export to BibTeX Export to EndNote
Perrone-filardi P, Dellegrottaglie S, Rudd JH, Costanzo P, Marciano C, Vassallo E, Marsico F, Ruggiero D, Petretta MP, Chiariello M, Cuocolo A
* Molecular imaging of atherosclerosis in translational medicine (579 views)
Eur J Nucl Med (ISSN: 1619-7089, 1619-7070, 0340-6997), 2011 May; 38(5): 969-975.
Impact Factor: 4.991
View Export to BibTeX Export to EndNote
Del Vecchio S, Zannetti A, Fonti R, Pace L, Salvatore M
* Nuclear imaging in cancer theranostics (616 views)
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2007 Jun; 51(2): 152-163.
Impact Factor: 1.724
View Export to BibTeX Export to EndNote
* Genetics and management of locally advanced carcinomas of the head and neck: role of altered fractionation radiotherapy (196 views)
Future Sci Oa (ISSN: 2056-5623linking), 2018 Oct 26; 5(1): FSO347-FSO347.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Zannetti A, Iommelli F, Speranza A, Salvatore M, Del Vecchio S
* 3'-deoxy-3'-18F-fluorothymidine (FLT) PET/CT to guide therapy with epidermal growth factor receptor (EGFR) antagonists and Bcl-xL inhibitors in non-small cell lung cancer (614 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2012 Mar 1; 53(3): 443-450.
Impact Factor: 5.774
View Export to BibTeX Export to EndNote
Zannetti A, Iommelli F, Speranza A, Salvatore M, Del Vecchio S
* 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer (525 views)
J Nucl Med (ISSN: 1535-5667, 0161-5505, 1535-5667electronic), 2012 Mar 1; 53(3): 443-450.
Impact Factor: 5.774
View Export to BibTeX Export to EndNote
Perrone-filardi P, Dellegrottaglie S, Rudd JH, Costanzo P, Marciano C, Vassallo E, Marsico F, Ruggiero D, Petretta MP, Chiariello M, Cuocolo A
* Molecular imaging of atherosclerosis in translational medicine (579 views)
Eur J Nucl Med (ISSN: 1619-7089, 1619-7070, 0340-6997), 2011 May; 38(5): 969-975.
Impact Factor: 4.991
View Export to BibTeX Export to EndNote
Del Vecchio S, Zannetti A, Fonti R, Pace L, Salvatore M
* Nuclear imaging in cancer theranostics (616 views)
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2007 Jun; 51(2): 152-163.
Impact Factor: 1.724
View Export to BibTeX Export to EndNote
5 Records (5 excluding Abstracts).
Total impact factor: 18.263 (18.263 excluding Abstracts).
Total 5 year impact factor: 19.512 (19.512 excluding Abstracts).
Total impact factor: 18.263 (18.263 excluding Abstracts).
Total 5 year impact factor: 19.512 (19.512 excluding Abstracts).
617 views. Last view on Wednesday 01 February 2023, 10:56:01
ibb.cnr.it
